{
    "clinical_study": {
        "@rank": "158223", 
        "arm_group": [
            {
                "arm_group_label": "simvastatin", 
                "arm_group_type": "Experimental", 
                "description": "they will receive simvastatin in addition to radiation therapy"
            }, 
            {
                "arm_group_label": "control", 
                "arm_group_type": "Active Comparator", 
                "description": "they will receive radiation therapy only"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate the effect of simvastatin in combination with\n      radiotherapy on the clinical outcomes of patients with brain metastases."
        }, 
        "brief_title": "Simvastatin Effect on Radiation Therapy of Brain Metastases", 
        "condition": "Brain Metastases", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasm Metastasis", 
                "Neoplasms, Second Primary", 
                "Brain Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Despite current advances in therapies, the outcome for patients with brain metastases is\n      fatal. New therapeutic approaches, such as radiosensitizing agents, are needed to provide a\n      significant survival advantage for those patients. Statins have been reported to enhance the\n      efficacy of radiotherapy in addition to a neuroprotective effect. The aim of the study is to\n      evaluate the effect of simvastatin on the efficacy and safety of  radiation therapy in\n      patients with brain metastases and on improving patients' quality of life."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with measurable brain metastases\n\n          -  Age more than 18 years old\n\n          -  Patients should be planned for radiation therapy\n\n        Exclusion Criteria:\n\n          -  Renal dysfunction (more than 1 upper normal level)\n\n          -  Hepatic dysfunction (alanine aminotransferase (ALT) and/or aspartate aminotransferase\n             (AST)  >3 times the upper normal level )\n\n          -  Pregnancy or lactation.\n\n          -  Known hypersensitivity to simvastatin"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02104193", 
            "org_study_id": "PH CL 25"
        }, 
        "intervention": [
            {
                "arm_group_label": "simvastatin", 
                "description": "simvastatin 80 mg tablet once daily during the radiation therapy period in addition to radiation therapy 30 Gy delivered in 10 fractions over 2 weeks", 
                "intervention_name": "simvastatin in addition to radiation therapy", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "control", 
                "description": "radiation therapy 30 Gy delivered in 10 fractions over 2 weeks", 
                "intervention_name": "radiation therapy", 
                "intervention_type": "Radiation"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Simvastatin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "brain metastases", 
            "simvastatin", 
            "radiation therapy"
        ], 
        "lastchanged_date": "April 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cairo", 
                    "country": "Egypt", 
                    "zip": "11566"
                }, 
                "name": "Ain Shams university Hospitals"
            }, 
            "investigator": {
                "last_name": "May A Shawki, master", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effect of Simvastatin on the Clinical Outcome of Patients With Brain Metastases Treated With Radiation Therapy: a Pilot Study", 
        "other_outcome": [
            {
                "description": "measures the patient quality of life", 
                "measure": "quality of life", 
                "safety_issue": "No", 
                "time_frame": "baseline, after radiation therapy, 6 weeks, 18 weeks, 30 weeks, 42 weeks, 54 weeks"
            }, 
            {
                "description": "assess the patient cognitive function by the evaluation of Montreal cognitive assessment test score", 
                "measure": "cognitive function assessment using Montreal cognitive assessment test", 
                "safety_issue": "Yes", 
                "time_frame": "baseline, after radiation therapy, 6 weeks, 18 weeks, 30 weeks, 42 weeks, 54 weeks"
            }, 
            {
                "description": "evaluate serum IL-1 beta at baseline and after 2 weeks", 
                "measure": "serum interleukin -1 beta (IL-1 beta)", 
                "safety_issue": "No", 
                "time_frame": "baseline, after radiation therapy"
            }
        ], 
        "overall_contact": {
            "email": "docshak76@gmail.com", 
            "last_name": "Amr S Saad, M.D."
        }, 
        "overall_official": {
            "affiliation": "Faculty of Pharmacy- Ain Shams university", 
            "last_name": "May A Shawki, master", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Egypt: Ministry of Higher Education", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "brain CT/MRI will be done at baseline and 4 weeks after radiotherapy to evaluate the reduction in tumor size", 
            "measure": "a- Response rate", 
            "safety_issue": "No", 
            "time_frame": "4 weeks after radiation therapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02104193"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ain Shams University", 
            "investigator_full_name": "MAy Ahmed Shawki", 
            "investigator_title": "teaching assisstant", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "it measures time from treatment initiation to either progression or death from any cause", 
                "measure": "progression free and overall survival", 
                "safety_issue": "No", 
                "time_frame": "up to 1 year"
            }, 
            {
                "description": "any adverse/side effect will be evaluated", 
                "measure": "adverse effects", 
                "safety_issue": "Yes", 
                "time_frame": "during the treatment period"
            }
        ], 
        "source": "Ain Shams University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ain Shams University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}